divest

Eoneren Coherus BioSciences (NASDAQ:CHRS) announced on Thursday that it would receive $40M in cash upfront as part of an agreement to divest its biosimilar therapy Yusimry targeted at AbbVie’s (ABBV) blockbuster arthritis therapy Humira. The deal with Chinese drugmaker Hong Kong King-Friend Industrial Co. Ltd. closed on June 26, 2024,Continue Reading